文献速递心律失常

房颤患者血清神经丝轻链与心血管结局的关联

Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2026-01-01

该研究基于瑞士房颤队列(SWISS-AF)2311例房颤患者,中位随访8.0年,评估基线血清神经丝轻链(sNfL)与心血管结局的关系。结果显示sNfL每翻倍,主要血管事件(心血管死亡、非致死性卒中、非致死性心肌梗死复合终点)校正后风险比为1.35。sNfL与卒中、心血管死亡、心衰住院及全因死亡均显著相关,但与心肌梗死无显著关联。

要点

  • sNfL每翻倍,房颤患者主要血管事件校正后风险比1.35(95%CI 1.22-1.50)
  • sNfL升高与卒中、心血管死亡、心衰住院和全因死亡显著相关
  • sNfL与心肌梗死无显著关联(aHR 1.04,95%CI 0.81-1.34)

核心结论

  • 经多变量校正后,sNfL水平与房颤患者多种不良心血管事件及死亡相关
  • 血清NfL可能作为房颤患者心血管风险的生物标志物

研究设计与样本

  • 前瞻性、多中心、观察性队列研究,数据来自瑞士房颤队列(SWISS-AF)
  • 随访截至2025年4月23日,中位随访8.0年(IQR 5.2-9.0年)

主要发现

  • 2311例患者平均年龄73.2岁(SD 8.5),男性1683例(73%)
  • 中位随访期间发生665例首次主要血管事件,发病率为每100人年4.4例(95%CI 4.1-4.8)

关键数值与推荐

  • 主要血管事件定义为心血管死亡、非致死性卒中和非致死性心肌梗死的复合终点

临床怎么用

  • sNfL可作为房颤患者心血管风险分层的潜在生物标志物
  • sNfL升高提示需关注卒中、心衰住院和死亡风险

局限性

  • 该分析来自观察性队列研究,无法确立因果关系
  • 研究纳入自瑞士14家二级或三级医疗中心,结果的外推性可能受限
  • 未报告心肌梗死与sNfL的显著关联,单一生物标志物的临床决策价值尚需验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Serum neurofilament light chain (sNfL) is a blood-based biomarker initially investigated for neuronal injury and is elevated in patients with atrial fibrillation (AF). Whether sNfL is associated with other adverse outcomes in this population is less well studied. OBJECTIVE: To determine the association between sNfL and cardiovascular outcomes in patients with AF. DESIGN, SETTING, AND PARTICIPANTS: The Swiss Atrial Fibrillation Cohort (SWISS-AF) is a prospective, multicenter, observational cohort study. The present analysis included patients enrolled from April 2014 through August 2017, with follow-up until April 23, 2025. Data analysis was conducted in June 2025. SWISS-AF enrolled inpatients and outpatients across 14 secondary or tertiary care centers in Switzerland. This analysis included 2311 of 2415 (95.7%) patients with documented AF in SWISS-AF after the exclusion of 76 patients without sNfL measurements and 28 patients with missing follow-up data. EXPOSURES: Concentrations of sNfL were measured from baseline serum samples using an ultrasensitive single-molecule array assay. MAIN OUTCOMES AND MEASURES: The primary outcome was major vascular events (MVEs), defined as a composite of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction. Other outcomes included the individual components of MVEs, heart failure-related hospitalization, and all-cause mortality. RESULTS: Of 2311 included patients, mean (SD) age was 73.2 (8.5) years, and 1683 (73%) were male. Over a median (IQR) follow-up of 8.0 (5.2-9.0) years, there were 665 first MVE events, corresponding to an incidence per 100 patient-years of 4.4 (95% CI, 4.1-4.8). Every doubling of sNfL concentration was associated with an adjusted hazard ratio (aHR) for MVEs of 1.35 (95% CI, 1.22-1.50; P < .001). Increasing sNfL levels were associated with nonfatal stroke (aHR, 1.31; 95% CI, 1.09-1.57; P = .004), cardiovascular death (aHR, 1.36; 95% CI, 1.20-1.54; P < .001), heart failure-related hospitalization (aHR, 1.25; 95% CI, 1.11-1.41; P < .001), and all-cause mortality (aHR, 1.41; 95% CI, 1.27-1.56; P < .001) but not myocardial infarction (aHR, 1.04; 95% CI, 0.81 to 1.34; P = .76). CONCLUSIONS AND RELEVANCE: After multivariable adjustment, sNfL levels were associated with a broad range of adverse cardiovascular events and mortality in patients with AF. Serum NfL may serve as a biomarker of cardiovascular risk in patients with AF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Baskaran, Krisai, Kühne, et al. Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation. JAMA Cardiol. 2026. PMID: 41904963. doi:10.1001/jamacardio.2026.0922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。